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Pirfenidone improves renal function and fibrosis in the post-obstructed
kidney.
Background. Pirfenidoney (PFD) is a novel anti-fibrotic agent that can
prevent and even reverse extracellular matrix accumulation in several
organs, as shown by experimental and clinical studies. Unilateral ureteral
obstruction (UUO) is a well-characterized model of experimental renal
disease culminating in tubulointerstitial fibrosis.
Methods. UUO or sham-operated rats were administered PFD (500
mg/kg/day) in their food for 21 days to examine the effect on collagen
production. The renal function was measured in the kidney after release of
obstruction which had been maintained for one week to examine the
effects of PFD on restoration after renal dysfunction.
Results. The collagen content detected by hydroxyproline progressively
increased in kidney with UUO for 21 days. These increases were signifi-
cantly suppressed by administration of PFD. PFD had no effect on
collagen production in sham-operated rats. Expression of mRNA for type
IV and I collagen and matrix metalloproteinase-2 in the cortex increased
with UUO, but was inhibited by PFD treatment. The levels of cortical
transforming growth factor-b (TGF-b) mRNA progressively rose with
UUO for 21 days, but this increase also could be suppressed by PFD.
Inulin clearance of the obstructed kidney was markedly depressed and
remained low at five weeks after release. A progressive increase in
hydroxyproline content was also observed in the post-obstructed kidney
despite the release of obstruction. Administration of PFD following the
release not only attenuated collagen accumulation, but also induced
recovery of the impaired renal function.
Conclusions. These results demonstrate that PFD can attenuate both
renal fibrosis and renal damage in this model, and suggest that PFD can
be clinically useful for preventing progressive, irreversible renal failure.
In recent years, decreases in the glomerular filtration
rate (GFR) due to different primary renal diseases have
been shown to be closely correlated to the degree of
changes in the tubulointerstitial area. Irrespective of the
underlying cause, many kidney diseases lead to tubuloin-
terstitial inflammation and eventual interstitial fibrosis with
permanent loss of renal function [1–5]. Most medical
investigators agree that new therapeutic strategies should
be targeted at developing effective methods for inhibiting
renal fibrogenesis. Although their therapeutic potential is
still under investigation, anti-fibrotic therapy holds great
promise for the prevention of renal disease that can
progress to end-stage renal failure.
Pirfenidone® (PFD) is a newly developed compound that
can prevent and even reverse extracellular matrix (ECM)
accumulation in several organs, as shown by experimental
studies of pulmonary fibrosis [6] and peritoneal sclerosis
[7]. In patients with end-stage pulmonary fibrosis, PFD not
only restored significant pulmonary function, but also im-
proved the survival rate. We have recently shown that PFD
can effectively prevent the development of progressive
renal disease in the monoclonal anti-Thy-1 antibody [8] and
the remnant kidney [9] rat model.
One well-characterized model of experimental renal
disease culminating in tubulointerstitial fibrosis uses
chronic unilateral ureteral obstruction (UUO) [10–15].
The impairment has been described as reversible at the
early stage [16]. However, prolonged obstruction frequently
leads to renal interstitial fibrosis and progressive destruc-
tion of the kidney [17]. Although the renal dysfunction
during or following the release of obstruction has been
linked to deterioration of the renal vasoacting system [18,
19], the mechanisms responsible for UUO-induced kidney
fibrosis are not well understood.
In the present study, to find further evidence of the
efficacy of PFD in chronic renal failure (CRF), we investi-
gated the effect of PFD on the development of tubuloin-
terstitial fibrosis induced by UUO. Furthermore, we en-
deavored to determine whether inhibition of interstitial
fibrosis by an anti-fibrotic agent could significantly contrib-
ute to an effective restoration of impaired renal function
resulting from fibrosis. We therefore tried to find whether
renal function could be improved by PFD treatment with of
rats with post-obstructed kidneys.
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METHODS
Animal study
Male Sprague-Dawley rats (8 weeks old at the start of the
experiment) were used in the study. Under light anesthesia
with pentobarbital, complete ureteral obstruction of the
left kidney was produced by ligating the ureter near the
bladder with a 4-0 silk suture through a small abdominal
incision. Sham-operated rats had their ureters manipulated
but not ligated. The incision was closed, and the animals
were allowed free access to tap water and standard chow
with or without PFD. In some experiments, administration
of PFD was started seven days subsequent to the obstruc-
tion. PFD was administered by an admixture in the food at
a concentration (0.6 to 0.9%) estimated to deliver approx-
imately 500 mg/kg/day of PFD. Rats with UUO were
sacrificed under pentobarbital anesthesia after 3, 7, 14, and
21 days from the start of the study.
After one week following UUO, the obstruction was
released in another series of rats. The suprapubic suture
was removed under light anesthesia. The ureteral obstruc-
tion was released by inserting a PE-50 catheter above the
ligature of the left ureter made one week earlier, and the
other end of the catheter was placed into the bladder to
drain urine. The incision was again closed, and the animals
were allowed free access to water and food with or without
PFD until the clearance studies were performed.
Clearance study
Clearance studies were performed at one, two and five
weeks after the release of the occlusion as previously
described [20, 21]. On the day of the clearance study, each
rat was anesthetized with pentobarbital (40 mg/kg body wt,
i.p.) and kept on a heated table. A femoral artery and vein
were cannulated with PE-50 tubing for blood sampling and
measurement of arterial pressure and for supplemental
infusion of solution, respectively. Urine samples from the
obstructed and/or contralateral kidney were obtained re-
spectively from each side, which cut the transplanted
ureteral catheter into two pieces. Urine volume was deter-
mined by weighing the urine collected in pre-weighed
tubes. A priming dose (20 mg/kg body wt) of inulin was
given as a bolus into the femoral vein, followed by contin-
uous infusion of 3% inulin at 30 ml/min. Samples from
animals with mean arterial pressure of less than 85 mm Hg
were excluded because they were considered to be aber-
rant. After an equilibration period, two consecutive 15-
minute urine specimens were collected. The mean of these
samples was used as a representative value for each animal.
Arterial blood samples were obtained at the midpoint of
each clearance period to determine the inulin concentra-
tions. Inulin concentration in plasma and urine samples
were measured by fluorometry using a previously described
method [22]. At the end of the experiment, each rat was
euthanized with an anesthetic overdose, and the kidney was
rapidly removed and subjected to measurement of collagen
content and morphometric examination.
Biochemical study
Collagen accumulation was evaluated for up to 21 days of
UUO. On the day of examination, the rats were anesthe-
tized with pentobarbital. The kidneys were removed and
sectioned longitudinally. After the medulla was removed,
the kidney was bisected with a sagittal cut. Half of the
cortex was used for determination of hydroxyproline and
protein, and the other half for extraction of total RNA.
Determination of hydroxyproline and protein
The collagen content in the renal cortex was assessed by
determining total hydroxyproline according to the method
of Wessner [23]. Briefly, the samples were suspended in 6 N
HCl and hydrolyzed for three hours at 130°C in tightly
capped tubes. The samples were then dried and resus-
pended in citrate-acetate buffer (pH 6.0). The samples
were oxidized by chloramine T and mixed with p-dimeth-
ylamino-benzaldehyde, then the absorbance at 557 nm was
measured. Hydroxyproline content was calculated from a
standard curve constructed with hydroxy-L-proline. The
results were expressed as hydroxyproline per mg protein.
Protein was determined according to Lowry et al [24]
with bovine serum albumin as a standard.
Total RNA extraction and Northern blot analysis
Total RNA was extracted from the renal cortex by the
acid-guanidinium thiocyanate-phenol-chloroform method
[25]. Cortical tissue weighing 50 to 100 mg was dispersed at
4°C in 4 ml of 4 M guanidine thiocyanate, containing 0.5%
sodium sarcosyl and 0.7% 2-mercaptoethanol, with a Poly-
tron homogenizer. The homogenate was mixed with 0.4 ml
of 2 M sodium acetate, pH 4.0, 4 ml of phenol, and 0.8 ml
of chloroform-isoamylalcohol (49:1, vol/vol) and kept on
ice for 20 minutes. The sample was centrifuged at 10,000 3
g for 20 minutes, and the aqueous phase was subjected to
phenol-chloroform extraction. RNA in the aqueous phase
was precipitated with isopropanol, collected by centrifuga-
tion at 15,000 3 g for 20 minutes, washed with 75%
ethanol, solubilized in diethylpyrocarbonate-treated water,
and stored at 270°C. The concentration of the RNA
isolated was calculated on the basis of absorbance at 260
nm. Aliquots of total RNA, each consisting of 10 mg, were
size-fractionated by electrophoresis in denaturing 1.0%
agarose/2.2 M formaldehyde gels in 20 mM MOPS buffer,
transferred overnight by capillary blotting in 10 3 SSC (1.5
M NaCl, 0.15 M sodium citrate, pH 7.0) to S&S Nytran nylon
membrane (Schleicher & Schuell, Keene, NH, USA), and
fixed to the membrane by exposure to UV.
Blots were prehybridized for four hours at 65°C in 5 3
SSC, 53 Denhardt’s solution (0.1% bovine serum albumin,
Ficoll, and polyvinylpyrrolidine), 50 mM sodium phosphate,
pH 6.5, 0.1% SDS, 250 mg/ml sonicated salmon sperm
DNA, and 50% formamide. Hybridization was performed
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for 24 hours at 65°C with a 32P-labeled cDNA probe in a
fresh prehybridization buffer supplemented with 10% dex-
tran sulfate. The cDNA probes were labeled with
[32P]dCTP (Du Pont-New England Nuclear, Boston, MA,
USA) to .1 3 108 cpm/mg using a random primer labeling
system (Gibco-BRL, Gaithersburg, MD, USA). Following
hybridization, the membranes were washed once in 2 3
SSC for 15 minutes at room temperature and twice in 0.2 3
SSC with 0.1% SDS for 15 minutes at 65°C. The mem-
branes were exposed to Kodak X-Omat X-ray films for one
to two days at 270°C with an intensifying screen. The blots
were stripped and reprobed with 28S or 18S ribosomal
RNA using the conditions of labeling, hybridization, and
washing as described above. The levels of mRNA were
quantitated by densitometry using an optical scanner sys-
tem (Fujix, BAS-2000II; Fuji Film Inc., Tokyo, Japan),
normalized to that of 28S or 18S ribosomal RNA to correct
for the difference in RNA loading and/or transfer.
The cDNAs used were a 1.3 kb PstI/BamHI fragment of
Pa1R1 for rat a1 (I) collagen [26], a 2.1 kb EcoRI fragment
of matrix metalloproteinase (MMP)-2 [27], and a 1.2 kb
Bgl P fragment of TGF-b [28]. The portion of the major
triple helical domain of the mouse a1(IV) chain encoding
the 1.05 kb PstI fragment [29] was subcloned and a 0.61 kb
PstI/PuvII fragment containing nucleotides 410-997 was
used as the cDNA probe for type IV collagen (MUSOL4A1
from GenBank).
Histological study by light microscopy
Half of the kidney was fixed in phosphate-buffered
formalin solution and processed in the usual manner. The
sections up to 2 mm thick were embedded in paraffin wax
and stained using routine techniques with PAM (periodic-
acid-methenamine silver).
Fig. 1. Effect of Pirfenidone (PFD) on body weight in rats with ureteral
obstruction. Data are represented as mean 6 SE. The number of animals
per group is shown in parenthesis below each bar. Symbols are: (M)
unilateral ureteral obstruction (UUO) rats without PFD treatment; (f)
UUO rats with PFD after the onset of obstruction; (o) UUO rats with
PFD from day 7 after obstruction.
Fig. 2. Effect of Pirfenidone (PFD) on hydroxyproline content as the
measurement of collagen in the kidney cortex of rats with ureteral
obstruction (A) and sham-operated controls (B). Data are represented as
mean 6 SE. Symbols are: (M) unilateral ureteral obstruction (UUO) rats
without PFD treatment; (f) UUO rats with PFD after the onset of
obstruction; (o) UUO rats with PFD from day 7 after obstruction. *P ,
0.05 versus untreated control group in each period. Numerals in paren-
theses show the number of animals.
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Statistical analysis
All results are expressed as mean 6 SE. Statistical
analysis was performed using Student’s t-test for paired or
unpaired samples as appropriate. P , 0.05 was considered
statistically significant.
RESULTS
Rates of weight gain were fairly comparable in all groups
except for the first three days after operation when there
was no weight gain (Fig. 1). There were no significant
differences in the mean body weights for each time interval
among the various groups, suggesting that total food intake
was comparable in the groups for the entire study period.
Accumulation of collagen in renal cortex during
unilateral ureteral obstruction
To determine the development of renal fibrosis, the
amount of collagen in the renal cortex was quantitatively
assessed by measuring the total content of hydroxyproline.
Changes in this content after UUO are shown in Figure 2.
In the obstructed kidney, the hydroxyproline content of the
renal cortex increased progressively to 21 days (Day 0:
baseline control, 12.3 6 0.8 mg/mg protein). The increased
collagen content was evident after only three days of
obstruction. At 3, 7, 14 and 21 days after obstruction, the
hydroxyproline content of the obstructed kidney increased
to 110%, 146%, 222% and 306%, respectively. This in-
crease could be significantly reduced by PFD at 14 and 21
days of UUO (178% and 183%, respectively). Even when
treatment with PFD was delayed for seven days after
obstruction, a significantly lower hydroxyproline content
was observed at 14 days. Thus, progressive accumulation of
collagen occurred in the renal cortex of the obstructed
kidney and, in the late phase of UUO, this increase could
be reduced by PFD. In contrast, PFD had no effect on the
hydroxyproline content in the kidney of the sham-operated
rats up to 21 days.
Expression of mRNA for type IV and I collagen, MMP-2
and TGF-b during UUO
To determine whether the increased collagen accumula-
tion found in the obstructed kidney is associated with
increases in mRNA levels for type IV and I collagen,
Northern blot analysis was performed on total RNA pre-
pared from the renal cortex. Results of a representative
study are shown in Figure 3A. The mRNA levels for type
IV collagen in the obstructed kidney were significantly
higher than those at the level of Day 0 (baseline). The type
Fig. 3. Northern blot analysis of mRNA for
type IV and I collagen, MMP-2 and 18S rRNA.
(A) Typical autoradiograms for type IV (5.0
and 6.8 kb) and type I (4.7 and 5.7 kb) collagen
and MMP-2 (3.1 kb) mRNA and 18S (1.9 kb)
rRNA in the cortex of sham-operated rats
(lanes 1 and 2), unilateral ureteral obstruction
(UUO) for three days (lanes 3 and 4), UUO
for seven days (lanes 5 and 6) and UUO for 14
days (lanes 7 and 8). UUO rats with PFD
treatment (lanes 4, 6 and 8). (B) Quantitation
of the mRNA. Data represent mean 6 SE.
Symbols are: (M) UUO rats without PFD
treatment; (f) UUO rats with PFD after the
onset of obstruction. *P , 0.05 versus
untreated control group in each period.
Numerals in parentheses show the number of
animals.
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IV collagen mRNA expression reached maximum levels by
seven days of UUO and then declined somewhat but
remained higher than the baseline levels. In rats treated
with PFD, increases in type IV collagen mRNA expression
were significantly reduced at 14 and 21 days of UUO.
Hybridization with the 18S rRNA control probe confirmed
that equivalent amounts of RNA were loaded in each lane.
The results of Northern analysis for mRNA were quanti-
tated by densitometry, normalized to that of 18S rRNA
(Fig. 3B). Likewise, expression of type I collagen mRNA
was also increased in the obstructed kidney with a time
course and effects of PFD comparable with that of type IV
collagen mRNA. As shown by the representative example
(Fig. 3A) and quantitalive analysis (Fig. 3B), type I collagen
mRNA was increased by three days after initiation of
UUO, peaking at seven days and remaining at a high level
at 21 days after kidney obstruction. In PFD-treated ani-
mals, a significant reduction of increased type I collagen
mRNA expression was observed at 21 days of UUO. These
results demonstrate that in the obstructed kidney, mRNA
levels for both type IV and I collagen increased to a
maximum within three days of UUO and remained ele-
vated until 21 days of UUO. Similar to the increases in
hydroxyproline content, the increase in collagen mRNA
expression was inhibited by PFD after 14 days, but not after
seven days of UUO. Because evidence of a clearer response
to PFD was observed in type IV collagen expression, our
data suggest that the change in type IV collagen mRNA
affords a greater contribution to the inhibition of collagen
accumulation by PFD than that of type I collagen.
Since persistent accumulation of collagen occurring in
the obstructed kidney might involve alterations in ECM-
degrading pathways, we examined mRNA expression of
matrix metalloproteinase (MMP)-2 (Fig. 3). The mRNA
level of MMP-2 increased by UUO, which was in parallel
with the data from collagen accumulation as well as the
collagen mRNA data, and the expression reached its
maximum by seven days after UUO. PFD showed effective
inhibition at 14 and 21 days. These data suggested that
collagen accumulation in UUO was independent of the
inactivation of the collagen degrading system, and that
PFD administration had no effect on this system in the
present study.
To study the role of TGF-b in the regulatory process
following UUO, we examined the expression of TGF-b
mRNA. As shown in Figure 4, the mRNA levels for TGF-b
in UUO rats increased remarkably in a manner similar to
collagen accumulation. The levels in the obstructed kidney
were significantly higher by three days and progressively
increased at 21 days of UUO. Administration of PFD
significantly inhibited increases in TGF-b mRNA after
seven days of UUO. PFD was still effective even when
treatment was delayed until seven days after initiation of
UUO.
Collagen accumulation and functional recovery of the
kidney following relief of UUO
Body and kidney weights in the clearance study are
shown in Tables 1 and 2. No significant differences in body
weight and contralateral kidney weight were found between
Fig. 3. Continued.
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the UUO groups with or without PFD. However, the
obstructed kidney in the UUO rats was significantly heavier
than that of the contralateral non-obstructed kidney at one
and two weeks after the release of UUO. This increase of
the kidney weight was inhibited by PFD at two weeks. Five
weeks after release of UUO, the weight of the obstructed
kidney tended to decrease compared with the contralateral
non-obstructed kidney. There was no significant difference
between the weight of the obstructed kidney in two the
Fig. 4. Northern blot analysis of mRNA for
TGF-b and 28S rRNA. (A) Typical
autoradiograms for TGF-b (2.5 kb) mRNA and
28S (4.7 kb) rRNA in the cortex of sham-
operated rat (lane 1), UUO for three days
(lane 2), UUO for seven days (lanes 3, 4, 5 and
6) and UUO for 14 days (lanes 7 and 8). UUO
rats with PFD treated (lanes 4, 6 and 8). (B)
Quantitation of the mRNA. Data are
represented as mean 6 SE. Symbols are: (M)
control; (f) preventive dose of PFD; (o)
therapeutic dose of PFD. *P , 0.05 versus
untreated control group in each period.
Numbers in parentheses show the number of
animals.
Table 1. Body weight (grams) of clearance study groups
Weeks after release of UUO
1 2 5
Sham-operated 396 6 3 (6) ND ND
Untreated control 300 6 10 (3) 342 6 7 (8) 430 6 8 (6)
PFD treated 296 6 4 (5) 329 6 6 (7) 420 6 9 (6)
Data are expressed the mean 6 SE. Number of rats is in parentheses.
ND is not determined in this study. Abbreviations are: UUO, unilateral
ureteral obstruction; PFD, Pirfenidone.
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groups of UUO rats. There was no significant difference
between blood pressure in the post-obstructed rats and in
sham-operated rats for the periods studied (Table 3).
We examined the effect of PFD administration on
collagen accumulation following release of obstruction
after seven days of UUO (Fig. 5). In spite of the cancella-
tion of the primary disorder by removal of the obstruction,
a progressive increase of hydroxyproline content was still
observed in the obstructed kidney. This increase was sig-
nificantly reduced by PFD. Furthermore, this improvement
remained significant 14 days after removal of the obstruc-
tion. In contrast with the untreated UUO group, no further
increase of the hydroxyproline content was observed by five
weeks in the PFD-treated group.
We next examined the effect of PFD on the renal
dysfunction persisting after release of the obstruction after
UUO. Inulin clearance was determined under anesthesia
following administration of PFD by five weeks after release
from UUO (Fig. 6). As compared with the contralateral
non-obstructed kidney or sham-operated kidney, inulin
clearance was markedly depressed in the post-obstructed
kidney and remained at a low level throughout the obser-
vation period. No significant improvement was found after
Fig. 5. Effect of PFD on cortical hydroxyproline content of obstructed
kidney after the release of obstruction lasting one week. Data are
represented as mean 6 SE. The number of animals per group is shown in
parentheses below each bar. Symbols are: (o) sham-operated rat; (f)
obstructed, untreated control rat; (M) obstructed, PFD treated rat; (j)
contralateral, untreated control rat; (u) contralateral, PFD treated rat.
*P , 0.05 between with and without PFD treated groups in the same
period; NS, not significant.
Fig. 6. Effect of PFD on inulin clearance of obstructed kidney after the
release of obstruction lasting one week. Data are represented as mean 6
SE. Number of animals per groups is shown in parenthesis below each bar.
Symbols are: (o) sham-operated rat; (f) obstructed, untreated control
rat; (M) obstructed, PFD treated rat; (j) contralateral, untreated control
rat; (u) contralateral, PFD treated rat. *P , 0.05 between with and
without PFD treated groups in same period; NS, not significant.
Table 2. Kidney weight (grams) of clearance study groups
Weeks after release of UUO
1 2 5
C UUO C UUO C UUO
Sham-operated 1.21 6 0.01 1.24 6 0.01 ND ND
Untreated control 1.28 6 0.14 1.36 6 0.09 1.25 6 0.03 1.43 6 0.05a 1.64 6 0.02 1.42 6 0.14
PFD treated 1.14 6 0.03 1.34 6 0.07a 1.27 6 0.04 1.28 6 0.05 1.54 6 0.11 1.45 6 0.08
Data are expressed as the mean 6 SE.
Abbreviations are: C, control kidney; UUO, unilateral obstructed kidney; ND, not determined in this study. Number of animals is same in Table 1.
a P , 0.05 compared to contralateral kidney
Table 3. Mean arterial pressure (mm Hg) of clearance study groups
Weeks after release of UUO
1 2 5
Intact (sham) 104 6 4 (6) ND ND
Control 107 6 7 (3) 105 6 3 (8) 99 6 5 (6)
PFD 116 6 6 (5) 111 6 3 (7) 103 6 4 (6)
Data are expressed the mean 6 SE. Number of rats is in parentheses.
ND is not determined in this study.
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two weeks following relief of obstruction in both the
untreated and PFD-treated groups. However, administra-
tion of PFD for five weeks significantly improved inulin
clearance. As compared with the untreated group, inulin
clearance of the contralateral non-obstructed kidney was
not different between the two groups with or without PFD
Fig. 7. Representative photomicrograph of PAM-stained sections from post-obstructed kidney five weeks after relief of obstruction lasting one week.
(A) Normal cortex in contralateral non-obstructed kidney (320, left; 350, right). (B) Weakly positive staining was observed in the obstructed kidney
after one week (320, left; 350, right). (C) A section of UUO showing a focal area of interstitial fibrosis and widened interstitial spaces in the kidney
at five weeks after removal of the one week of UUO (320, left; 350, right). (D) Necrosis and sloughing of tubules were less common in the PFD-treated
rats (320, left; 350, right).
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administration. These results indicate that PFD adminis-
tration can attenuate impairment of renal function follow-
ing removal of ureteral obstruction.
The histological appearance of the kidney at five weeks
after removal of the seven-day ureteral obstruction showed
variable and often extensive interstitial fibrosis. In compar-
ison to the weakly and sparsely positive staining in the
kidney cortex for the UUO after one week (Fig. 7B), strong
and extensive interstitial staining persisted at week 5 after
UUO release (Fig. 7C). There was widening of the inter-
stitial spaces and some degree of hypercellularity. Promi-
nent PAM positive staining was seen in the tubulointersti-
tial area. The glomeruli appeared to be generally well
preserved, but sometimes were stained more readily in the
glomerular area with periglomerular fibrosis. In mature
glomeruli, the staining suggested sclerosis. By contrast, the
PFD-treated animals showed striking attenuation of these
histological changes with very little fibrosis in the intersti-
tium (Fig. 7D). The histologic views of the obstructed
kidney were quite different from those of the contralateral
non-obstructed kidney (Fig. 7A).
DISCUSSION
Renal interstitial fibrosis displays the characteristic fea-
tures of chronic obstructive nephropathy. Although the
mechanisms responsible for UUO-induced kidney damage
are not well understood, the fibrogenic process certainly
leads to permanent loss of the normal integrity and func-
tion of the kidney. Clearly, relief of the obstruction is the
best therapeutic option [30]. However, according to our
data, prolonged obstruction induces progressive renal fi-
brosis with dysfunction which cannot be readily restored
even with removal of the obstruction. Under these circum-
stances, pharmacotherapeutic intervention needs to be
developed to reverse or halt the progression of the renal
dysfunction that occurs as a consequence of the obstruc-
tion. Furthermore, the development of progressive inter-
stitial fibrosis represents a final common pathway associ-
ated with a variety of kidney disorders that can lead to
functional insufficiency [1, 2, 5]. Thus, the search for
effective anti-fibrotic agents is of great importance not only
for elucidating the mechanism of UUO-induced fibrosis,
but also for alleviating the renal fibrosis seen under various
conditions with CRF.
In the present study, we employed biochemical measures
to quantitatively examine the processes of fibrogenesis in
UUO. Our findings demonstrated that ureteral obstruction
results in an accumulation of collagen in a time-dependent
manner in the renal cortex of the obstructed kidney. The
UUO-induced increase in the kidney hydroxyproline con-
tent was significantly inhibited by oral daily treatment with
PFD for two to three weeks. Since accumulation of colla-
gen in the kidney is the hallmark of renal fibrosis, a
reduction in the collagen accumulation by PFD reflects its
anti-fibrotic effect. Although the mechanisms for the ame-
liorating effect of PFD on UUO-induced fibrosis are not
well understood, a decreased mRNA expression parallels a
reduction in the accumulation of collagen, indicating that
blocking renal fibrosis by PFD can prevent progressive
renal disease, which in turn is associated with the preven-
tion of an up-regulation of gene expression of collagen. As
noted in this study, PFD can inhibit collagen accumulation
when such accumulation is overexpressed. In contrast to
other collagen-modulator substances, such as tumor necro-
sis factor-a (TNF-a) [31], interleukin (IL)-1 [32] and
g-interferon (gINF) [33], PFD does not alter the basal
levels of collagen content. Therefore, PFD may be predom-
inantly efficacious in a pathologic condition and may have
the ability to normalize the over-expression of components
that contribute to fibrosis.
The pathological role of TGF-b for extracellular matrix
(ECM) accumulation in most forms of experimental ne-
phritis has been well established [34]. Recent publications
describing the signal that may trigger fibrosis have pointed
out that TGF-b is probably a major cytokine responsible
for the fibrotic reaction in normal tissue following various
exogenous insults [35]. The sustained aberrant expression
of renal TGF-b results in the pathologic accumulation of
ECM material in interstitial compartments. This points to
the challenge of determining which of the TGF-b-regulated
events makes a significant contribution to the intrarenal
fibrogenic process. We decided to examine the TGF-b gene
expression. Our data indicate that inhibition of the UUO-
induced increase of TGF-b mRNA in the kidney cortex
occurs a few days earlier than the inhibition of increased
collagen mRNA and is coincident with collagen accumula-
tion. Thus, inhibition of collagen production by PFD may
be mediated in part by the suppression of TGF-b. How-
ever, it remains unclear whether the decreased TGF-b
expression is due to a direct effect of PFD and/or through
a secondary mechanism accompanied by an anti-fibrotic
action.
Monocyte-macrophage infiltration has been implicated
as being pathogenetically important in cellular alterations
contributing to the process of tubulointerstitial fibrosis.
Indeed, such ED-1-positive cell infiltration was present in
the obstructed kidney in an early phase after ureteral
ligation [15]. Several cytokines secreted by infiltrating
macrophage and T-lymphocytes act as chemoattractants
and stimulate fibroblast proliferation. Such interstitial fi-
broblasts produce ECM protein and fibrosis. In addition,
the macrophage—TGF-b axis is a plausible potential mech-
anism in the overproduction of ECM that may eventually
cause interstitial fibrosis in the UUO model [36], since
TGF-b is known to be a strong chemoattractant for mono-
cytes [37]. Ishidoya et al [14, 15] found that enalapril, an
angiotensin converting enzyme (ACE) inhibitor, signifi-
cantly decreased the number of ED-1 positive monocytes
infiltrating the interstitium and that this decreased the
interstitial cellularity as well as contributed in part to the
reducing interstitial fibrosis in the obstructed kidney. Al-
though we have no evidence to indicate that there would be
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a PFD effect on the inflammatory component to the
response, the data in the present study showing that
administration of PFD does not reverse the increased
collagen accumulation in the acute phase of UUO offer
little, if any, possibility for contribution from the adhesive-
ness of monocytes, which plays an essential role in mecha-
nisms responsible for the anti-fibrotic effect of PFD. How-
ever, Diamond et al have shown that the ED-1 positive cell
number does not reach maximum at seven days after UUO
[38]. Therefore, to negate this possibility, further evidence
is necessary to show that the effect of this treatment
modality on chemoattractant levels, such as macrophage
chemoattractant peptide-1 (MCP-1), intracellular adhesion
molecule-1 (ICAM-1) and osteopontin, before excluding
the effect of PFD on monocytic inflammation.
The other possible mechanism for the anti-fibrotic effect
of PFD in the UUO model is to minimize the reactive
oxygen species, because, as reported in a previous paper on
a study using the bleomycin-induced lung fibrosis model in
hamsters, PFD may prevent the initial bleomycin-induced
production of reactive oxygen species or block their injuri-
ous effect by scavenging them [6]. The possibility is
strengthened from the evidence that oxidant stress is
thought to be a factor in experimental hydronephrosis [39].
Since the accumulation of ECM results from a balance
between synthetic and degradative processes, a matrix-
degrading system may also play an important role in
regulating the turnover of collagen. To further define the
possible contribution of the degrading system, we observed
the effect on MMP-2, a matrix metalloproteinase, in UUO.
In the present study, the MMP-2 gene was markedly
induced by UUO. Therefore, it is less likely that depressed
MMP production induces the accumulation of collagen.
Furthermore, the anti-fibrotic effect of PFD does not
appear to be due to a change in the MMP level, because the
degree of its level was decreased by PFD administration.
However, since in the present study we did not measure the
activity of MMP per se, to establish the contribution of the
matrix degrading system for the mechanism of the anti-
fibrotic action of PFD, further studies are necessary to
ascertain the enzyme activity of these proteinases.
Furthermore, our observation in this model of chronic
interstitial injury after UUO seems paradoxical considering
the change of the increment between collagen mRNA and
hydroxyproline contents. Namely, the increase in type I and
IV collagen mRNA levels peaked at one week post-UUO
and declined when interstitial fibrosis was progressing. The
data therefore lead us to believe that interstitial fibrosis
may be due to decreased ECM degradation in the chronic
phase. Indeed, Engelmyer et al [40] and Sharma et al [41]
have demonstrated that there is impaired MMP activity by
up-regulation of tissue inhibitors of MMP (TIMP) expres-
sion after UUO, suggesting that regulation of TIMP activ-
ity may contribute to the inception of the fibrogenic
response. What remains to be determined is whether PFD
can inhibit the activity of TIMP to provide the potential
mechanism for the anti-fibrotic action.
The effects of obstruction on renal function depend upon
the duration and completeness of the obstruction [42].
With complete obstruction, the degree to which the func-
tion recovers strongly depends upon the duration of ob-
struction. Few studies are available on the degree of
recovery of renal function in humans [43], because of the
difficulty for surgical release of the feasibility. Provoost and
Molenaar [16] demonstrated that GFR, when measured in
rats up to two weeks after the release of obstruction for
varying periods of duration, recovered as much as 85%
after removal of obstruction that had lasted one week. In
contrast, Govan observed recovery after less than four days
of UUO but no recovery after longer periods and con-
cluded that repair did not occur [17]. These findings
coupled with other data [44, 45] indicate that in rats,
obstruction of two to three weeks is the maximum period
that allows some recovery of renal function after removal of
the obstruction. In the present study, functional recovery
was much slower. Inulin clearance recovered to only 23%
after the removal of UUO lasting one week against that of
sham-operated rat but there was significant recovery to
63% with PFD treatment. In the present study, we demon-
strated that reduction of UUO-induced collagen accumu-
lation by PFD preceded the recovery from a decreased
inulin clearance. These results clearly indicate that impair-
ment of renal function associated with renal fibrosis can be
substantially improved by the anti-fibrotic action of PFD.
Our finding that progressive renal fibrosis with dysfunction
cannot be readily restored in spite of removal of the
obstruction agrees with the evidence from Diamond et al,
who used this obstruction-release approach and found that
it took four weeks for osteopontin mRNA expression to
normalize after releasing the obstruction [38].
The morphologic observations of marked reduction in
the fibrotic lesions in PFD-treated UUO rats as compared
to the controls are encouraging. The reduced lesions in the
PFD group implies amelioration of UUO-induced injury
and suggests the possible therapeutic use of PFD in ob-
structive nephropathy.
In conclusion, PFD prevented UUO-induced interstitial
fibrosis, and this was accompanied by significantly im-
proved renal function. These experiments also demonstrate
that PFD can prevent the development of irreversible
progression of CRF in rats. Our results strongly support the
concept that PFD may offer a new and exciting possibility
for retarding the progression of human CRF.
Reprint requests to Toshikatsu Shimizu, Ph.D., Shionogi Research Labo-
ratories, Shionogi & Co., Ltd., 3-1-1, Futaba-cho, Toyonaka, Osaka 561,
Japan.
E-mail: toshikatsu.shimizu@shionogi.co.jp
REFERENCES
1. BOHLE A, MACKENSEN-HAEN S, GISE VH: Significance of tubuloin-
terstitial changes in the renal cortex for the excretory function and
Shimizu et al: Inhibition of renal fibrosis by Pirfenidone®108
concentration ability of the kidney: A morphometric contribution.
Am J Nephrol 7:421–433, 1987
2. KUNCIO GS, NELSON EG, HAVERTY T: Mechanism of tubulointersti-
tial fibrosis. Kidney Int 39:550–556, 1991
3. EL NAHAS AM: Pathway to renal fibrosis. Exp Nephrol 3:71–75, 1995
4. STRUTZ F, MULLER GA: The role of tubulo-interstitial processes in
progression of primary renal diseases. Nephrol Dial Transplant
9(Suppl):10–20, 1994
5. STRUZ F, MULLER GA: On the progression of chronic renal disease.
Nephron 69:370–379, 1995
6. IYER SN, WILD JS, SCHIEDT MJ, HYDE DM, MARGOLIN SB, GIRI S:
Dietary intake of Pirenidone ameliorates bleomycin induced lung
fibrosis in hamsters. J Lab Clin Med 125:779–785, 1995
7. SUGA H, TERAOKA S, OKA K, KOMEMUSHI S, FURUTANI S, YAMAUCHI
S, MARGOLIN SB: Preventive effect of Pirfenidone against experimen-
tal sclerosing peritonitis in rats. Exp Toxic Pathol 47:287–292, 1995
8. SHIMIZU F, FUKAGAWA M, YAMAUCHI S, TANIYAMA M, KOMEMISHI S,
MARGOLIN SB, KUROKAWA K: Pirfenidone prevents the progression
of irreversible glomerular sclerotic lesions. Nephrol 3:315–322, 1997
9. SHIMIZU T, FUKAGAWA M, KURODA T, HATA S, IWASAKI Y, NEMOTO
M, SHIRAI K, YAMAUCHI S, MARGOLIN SB, SHIMIZU F, KUROKAWA K:
Pirfenidone prevents collagen accumulation in the remnant kidney in
rats with partial nephrectomy. Kidney Int 52:(Suppl 63): S239–S243,
1997
10. KANETO H, MORRISSEY J, MCCRACKEN R, REYES A, KLAHR S:
Enalapril reduces collagen type IV synthesis and expression of the
interstitium in the obstructed rat kidney. Kidney Int 45:1637–1647,
1994
11. NAGLE RB, KNEISER MR, BULGER RE, BENDITT EP: Induction of
smooth muscle cell characteristics in renal interstitial fibroblasts
during obstructive nephropathy. Lab Invest 29:422–427, 1973
12. NAGLE PB, BULGER RE, CUTLER RE, JERVIS HR, BENDITT EP:
Unilateral obstructive nephropathy in the rabbit. I. Early morpho-
logic, physiologic, and histochemical changes. Lab Invest 28:456–467,
1973
13. SHARMA AK, MAUER SM, KIM Y, MICHAEL AF: Interstitial fibrosis in
obstructive nephropathy. Kidney Int 44:774–788, 1993
14. ISHIDOYA S, MORRISSEY J, MCCRACKEN R, REYES A, KLAHR S:
Angiotensin II receptor antagonist ameliorates renal tubulointerstitial
fibrosis caused by unilateral ureteral obstruction. Kidney Int 47:1285–
1294, 1995
15. ISHIDOYA S, MORRISSEY J, MCCRACKEN R, KLAHR S: Delayed treat-
ment with enalapril halts tubulointerstitial fibrosis in rats with obstruc-
tive nephropathy. Kidney Int 49:1110–1119, 1996
16. PROVOOST AP, MOLENAAR JC: Renal function during and after a
temporary complete unilateral ureter obstruction in rats. Invest Urol
18:242–246, 1981
17. GOVAN DE: Experimental hydronephrosis. J Urol 85:432–441, 1961
18. KLAHR S, ISHIDOYA S, MORRISSEY, J: Role of angiotensin II in the
tubulointerstitial fibrosis of obstructive nephropathy. Am J Kidney Dis
26:141–146, 1995
19. RINER CA HALLLUSHKA PV, SENS MA, PLOTH DW: Thromboxane A2
receptor blockade improves renal function and histopathology in the
post-obstructive kidney. Kidney Int 45:185–192, 1994
20. SHIMIZU T, NAKAMURA M: Renal effect of atrial natriuretic polypep-
tide: Comparison with standard saluretics. Eur J Pharmacol 127:249–
259, 1986
21. SHIMIZU T, NAKAMURA M, IMAI M: Renal action of a novel uricosuric
diuretics, S-8666. I. clearance and tubular microinjection studies in
rats. J Pharmacol Exp Ther 245:644–650, 1988
22. VUREK G, PEGRAM SE: Fluorometric method for the determination of
nanogram quantities of inulin. Anal Biochem 16:409–419, 1966
23. WOESSNER JF JR: The determination of hydroxyproline in tissue and
protein samples containing small proportions of this imino acid. Arch
Biochem Biophys 93:440–447, 1961
24. LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ: Protein
measurement with the folin phenol reagent. J Biol Chem 193:265–270,
1951
25. SHOMCZYNSKI P, SACCHI N: Single-step method of RNA isolation by
acid guanidinium thiocyanate-phenol-chloroform extraction. Anal
Biochem 162:156–159, 1987
26. GENOVERSE C, ROWE D, KREAM B: Construction of DNA sequences
complementary to rat a1 and a2 collagen mRNA and their use in
studying the regulation of type I collagen synthesis by 1,25-dihy-
droxyvitamin D. Biochem 23:6210–6216, 1984
27. HUHTALA P, EDDY RL, FAN YS, BYERS MG, SHOWS TB, TRYGGVASO
K: Completion of the primary structure of the human type IV
collagenase preproenzyme and assignment of the gene to the q21
region of chromosome. Genomics 6:554–559, 1990
28. DERYNCK R, JARRETT JA, CHEN EY, GOEDDEL DV: The murine
transforming growth factor-beta precursor. J Biol Chem 261:4377–
4379, 1986
29. WOOD L, THERAULT N, VOGELI G: cDNA clones completing the
nucleotide and derived amino acid sequence of the alpha 1 chain of
basement membrane (type IV) collagen from mouse. FEBS Lett
227:5–8, 1988
30. WILSON DR, KLAHR S: Urinary track obstruction, in Disease of the
Kidney (5th ed), edited by SCHRIER RW, GOTTSCHAK CW, Boston,
Little Brown, 1993, pp 657–687
31. SOLIS-HERRUZO JA, BRENNER DA, CHOJKIER M: Tumor necrosis
factor a inhibits collagen gene transcription and collagen synthesis in
cultured human fibroblasts. J Biol Chem 263:5849–5845, 1988
32. ARMENDARIZ-BORUNDA J, KATAYAMA K, SEYER JM: Transcriptional
mechanisms of type I collagen gene expression are differentially
regulated by interleukin-1b, tumor necrosis factor a, and transforming
growth factor b in Ito cells. J Biol Chem 267:14316–14321, 1992
33. AMENTO EP, BHAN AK, MCCULLAGH KG, KRANE SM: Influences of
gamma interferon on synovial fibroblastlike cells. Ia induction and
inhibition of collagen synthesis. J Clin Invest 76:837–848, 1985
34. ALVAREZ RJ, SUN MJ, HAVERTY TP, IOZZO RV, MYERS JC, NELSON
EG: Biosynthetic and proliferative characteristics of tubulointerstitial
fibroblasts probed with paracrine cytokines. Kidney Int 41:14–23, 1992
35. SHARMA K, ZIYADEH FN: The emerging role of transforming growth
factor-b in kidney disease. Am J Physiol 266:F829–F842, 1994
36. DIAMOND JR, KEES-FOLTS D, DING G, FRYE JE, RESTREPO NC:
Macrophages, monocyte chemoattractant peptide-1, and TGF-b1 in
experimental hydronephrosis. Am J Physiol 266:F926–F933, 1994
37. WAHL SM, HUNT DA, WAKEFIELD LM, MCCARTNEY-FRANSIS N,
WAHL LM, ROBERTS AB, SPORN MB: Transforming growth factor
type b induces monocyte chemotaxis and growth factor production.
Proc Natl Acad Sci USA 84:5788–5792, 1987
38. DIAMOND JR, KEES-FOLTS D, RICARDO SD, PRUZNAK A, EUFEMIO M:
Early and persistent up-regulated expression of renal cortical os-
teopontin in experimental hydronephrosis. Am J Pathol 146:1455–
1466, 1995
39. RICARDO SD, DING G, EUFEMIO M, DIAMOND JR: Antioxidant
expression in experimental hydronephrosis: Role of mechanical
stretch and growth factors. Am J Physiol 272:F789–F798, 1997
40. ENGELMYER E, VAN GOOR H, EDWARDS DR, DIAMOND JR: Differ-
ential mRNA expression of renal cortical tissue inhibitor of metallo-
proteinase-1, -2, and -3 in experimental hydronephrosis. J Am Soc
Nephrol 5:1675–1683, 1995
41. SHARMA AK, MAUER SM, KIM Y, MICHAEL AF: Altered expression of
matrix metalloproteinase-2, TIMP, and TIMP-2 in obstructive ne-
phropathy. J Lab Clin Med 125:754–761, 1995
42. YARGER WE: Urinary track obstruction, in The Kidney (4th ed), edited
by BRENNER BM, RECTOR FC JR, Philadelphia, Saunders, 1991, pp
1768–1808
43. JONES DA, GEORGE NJR, O’REILLY PH, BARNARD J: The biphasic
nature of renal functional recovery following relief of chronic obstruc-
tive uropathy. Brit J Urol 61:192–197, 1988
44. DAL CANTON A, CORRADI A, STOMZIALE R, MARUCCIO G, MIGONE L:
Effects of 24-hour unilateral ureteral obstruction on glomerular
hemodynamics in rat kidney. Kidney Int 15:457–462, 1979
45. VAUGHAN ED JR, GILLENWATER JY: Recovery following complete
chronic unilateral occlusion. Functional radiographic and pathological
alterations. J Urol 106:27–35, 1971
Shimizu et al: Inhibition of renal fibrosis by Pirfenidone® 109
